Effect of glimepiride on the pharmacokinetics of teneligliptin in healthy Korean subjects.
What is known and objective: Teneligliptin is a DPP‐4 inhibitor used for the treatment of type 2 diabetes mellitus, commonly prescribed in combination with glimepiride. Teneligliptin is metabolized by CYP3A4, and glimepiride might be partly metabolized by CYP3A4. The aim of the study was to investig...
| Publicado en: | Journal of Clinical Pharmacy & Therapeutics Vol. 44; no. 5; pp. 720 - 726 |
|---|---|
| Autores principales: | , , , , |
| Formato: | clinical trial research tables/charts Journal Article |
| Publicado: |
Wiley-Blackwell
Oct2019
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=138441633&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 138441633 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 02694727 EV4 jtl: Journal of Clinical Pharmacy & Therapeutics issn: 02694727 maglogo: Y pubinfo: dt: Oct2019 vid: 44 iid: 5 pid: 480 pub: Wiley-Blackwell place: Malden, Massachusetts artinfo: ui: 138441633 138441633 138441633 10.1111/jcpt.12848 138441633 ppf: 720 ppct: 6 formats: fmt: – @attributes: type: T – @attributes: type: C – @attributes: type: P tig: atl: Effect of glimepiride on the pharmacokinetics of teneligliptin in healthy Korean subjects. aug: au: Park, Jin‐Woo Kim, Kyoung‐Ah Choi, Yun Jung Yoon, Soo Hyun Park, Ji‐Young affil: Department of Clinical Pharmacology and Toxicology, Korea University College of Medicine, Korea University Anam Hospital, Seoul Korea sug: subj: Glimepiride Pharmacodynamics Dipeptidyl Peptidase 4 Inhibitors Pharmacokinetics Drug Interactions Human South Korea Clinical Trials Dipeptidyl Peptidase 4 Inhibitors Administration and Dosage Glimepiride Administration and Dosage Dipeptidyl Peptidase 4 Inhibitors Metabolism Dipeptidyl Peptidase 4 Inhibitors Blood Time Factors Descriptive Statistics Confidence Intervals ab: What is known and objective: Teneligliptin is a DPP‐4 inhibitor used for the treatment of type 2 diabetes mellitus, commonly prescribed in combination with glimepiride. Teneligliptin is metabolized by CYP3A4, and glimepiride might be partly metabolized by CYP3A4. The aim of the study was to investigate the possible effect of glimepiride on the pharmacokinetics of teneligliptin in healthy subjects. Methods: A repeated dose, open‐label, fixed‐sequence study was conducted in 26 healthy subjects. All participants were administered 20 mg teneligliptin daily for 6 days. On day 7, 4 mg glimepiride was administered together with 20 mg teneligliptin. Plasma teneligliptin concentrations were measured at a steady state, and its pharmacokinetic characteristics were compared without and with glimepiride. Results and discussion: No statistically significant difference was found in the effect of glimepiride on teneligliptin pharmacokinetics. The steady‐state Cmax,ss values of teneligliptin without and with glimepiride were 207.01 ng/mL and 202.15 ng/mL, respectively. Its AUCτ values at steady‐state without and with glimepiride were 1527.8 ng · h/mL and 1578.6 ng · h/mL, respectively. The point estimation of geometric mean ratios (GMR) and the 90% confidence interval for both Cmax,ss and AUCτ were within the equivalence range of 0.8‐1.25. The results of the present study revealed that glimepiride did not cause pharmacokinetic interaction with teneligliptin in humans. What is new and conclusion: Glimepiride did not affect the pharmacokinetic characteristics of teneligliptin in healthy subjects. pubtype: Academic Journal doctype: clinical trial research tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|